BioGaia ABBGLAF 100 Net Current Asset Value is $1.09 as of Mar. 2026, which is 91% below its 10-year median of 12.43. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05 (Fairly Valued). The stock has 5 warning signs investors should review. Among 612 Drug Manufacturers companies, BioGaia AB ranks worse than 75.49% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
BioGaia AB's net current asset value per share for the quarter that ended in Mar. 2026 was $1.09.
The historical rank and industry rank for BioGaia AB's Net Current Asset Value or its related term are showing as below:
BGLAF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.3 Med: 12.43 Max: 34.22
Current: 11.73
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of BioGaia AB was 34.22. The lowest was 5.30. And the median was 12.43.
BGLAF's Price-to-Net-Current-Asset-Value is ranked worse than 75.49% of 612
companies
in the Drug Manufacturers industry
Industry Median: 5.4
vs BGLAF: 11.73
BioGaia AB (OTCPK:BGLAF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
BioGaia AB Net Current Asset Value Related Terms
BioGaia AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLAF vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.09 mean?
BioGaia AB (BGLAF) has a Net Current Asset Value of $1.09 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioGaia AB and its competitors. This is 91% below median its historical median of 12.43. Over the past decade, BioGaia AB's Net Current Asset Value has ranged from 5.30 to 34.22. According to the industry distribution chart, BioGaia AB ranks #462 out of 612 companies in the Drug Manufacturers industry, placing it in the top 75.5%.
Is BioGaia AB's Net Current Asset Value too high?
BioGaia AB's current Net Current Asset Value of $1.09 is 91% below median its 10-year median of 12.43. Over the past 10 years, this metric has ranged from a low of 5.30 to a high of 34.22. The Drug Manufacturers industry median Net Current Asset Value is 5.40. BioGaia AB's value of $1.09 is 79.8% below this industry median. Based on the distribution chart, BioGaia AB ranks #462 out of 612 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #462 out of 612 companies for Net Current Asset Value. This places BioGaia AB in the lower half of its industry. The industry median Net Current Asset Value is 5.40. BioGaia AB's value of $1.09 is 79.8% below this benchmark. Historically, BioGaia AB's own Net Current Asset Value has ranged from 5.30 to 34.22 over the past decade. While the company's 10-year median is 12.43 vs. the industry median of 5.40, BioGaia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.40, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Net Current Asset Value of $1.09 is 79.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Net Current Asset Value is $1.09, which is 91% below median its own 10-year median of 12.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Net Current Asset Value is $1.09, which is 91% below median its 10-year median of 12.43 and 79.8% below the Drug Manufacturers industry median of 5.40. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Net Current Asset Value is $1.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Net Current Asset Value: $1.09 (91% below median its 10-year median of 12.43)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 79.8% below the Drug Manufacturers median (#462 of 612)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
